ABSORB III at 2 years: more events, more difference
ABSORB III presented at ACC consolidate the understanding that bioresorbable scaffolds carry a higher risk of target lesion failure compared with their metallic counterpart
Reported from the American College of Cardiology 2017 Scientific Sessions in Washington.
After the positive report of the 1-year results of ABSORB III, showing noninferiority compared with everolimus-eluting stents, one may have thought that the story of bioresorbable scaffolds would have been finally smooth and easy. The 3-year results of ABSORB II sounded disturbing at the end of last year, and now the 2-year results of ABSORB III presented at ACC consolidate the understanding that bioresorbable scaffolds carry a higher risk of target lesion failure compared with their metallic counterpart.
The greater part of the presentation of this trial update was spent going into the details of these disappointing results, suggesting that better implantation techniques would have translated into better outcomes. Unfortunately, there is no way to prove that without conducting a new trial.
ABSORB IV, which leverages on lessons from prior trials to provided a recommended implantation protocol (the so-called PSP) anticipated to mitigate the risk of scaffold thrombosis and target lesion failure, will now be expected to provide convincing safety data for a promising but perhaps immature technology.